![Calvin Yu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Cleveland | M | 67 | 4 years | |
Thomas Chalberg | M | 46 | 9 years | |
Hans Hull | M | 49 | 4 years | |
Luis Borges | M | 62 | 5 years | |
Julia Gregory | F | 71 | 3 years | |
Mark Blumenkranz | M | 73 | 10 years | |
Mehdi Gasmi | M | 57 | 6 years | |
Linda Bain | F | 53 | 1 years | |
Francis Sarena | M | 53 | 11 years | |
Jennifer Cheng | M | 51 | 4 years | |
Franklin Berger | M | 74 | 11 years | |
Peder Jensen | M | 69 | 10 years | |
Min MIn Qin | M | 66 | 7 years | |
Phillip Eric Lee | M | 37 | 1 years | |
Galya Blachman | M | 47 |
Stemcentrx, Inc.
![]() Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | 5 years |
Nallakkan S. Arvindan | M | - | 9 years | |
Anna L. Barry | M | - | 3 years | |
Michael Swartzburg | M | 57 | - | |
Roman Rubio | M | 53 | 2 years | |
Julie Hambleton | M | 66 | 4 years | |
Jeffrey Finer | M | - | 4 years | |
Shirley Braun | M | - | 1 years | |
Brook Byers | M | 78 | - | |
Kee-Hong Kim | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 24 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Calvin Yu
- Personal Network